학술논문

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients
Document Type
Article
Author
Bruel, TimothéeVrignaud, Lou-LénaPorrot, FrançoiseStaropoli, IsabellePlanas, DelphineGuivel-Benhassine, FlorencePuech, JulienProt, MatthieuMunier, SandieBolland, William HenrySoulié, CathiaZafilaza, KarenLusivika-Nzinga, ClovisMeledge, Marie-LaureDorival, CélineMolino, DianaPéré, HélèneYordanov, YouriSimon-Lorière, EtienneVeyer, DavidCarrat, FabriceSchwartz, OlivierMarcelin, Anne-GenevièveMartin-Blondel, GuillaumeGarcia, MagalieGiraud, ValentinMetais, AgatheCazenave-Roblot, FanceMartellosio Anne-Marie Ronchetti, Jean-PhilippeGabas, ThomasHadjadj, NaimaSalanoubat, CéliaChabrol, AmélieHousset, PierrePardon, AgatheFaucon, Anne-LaureCaudwell, ValérieRoland Liblau, Latifa HanafiAlric, LaurentPugnet, GrégoryMourguet, MorganeBories, EvaBonnet, DelphineCharpentier, SandrineDelobel, PierreDebard, AlexaBeck, ColleenBoumaza, XavierFanny Lanternier, Stella RoussetDelage, ClairePires, Elisabete GomesCheminant, MorganeAnthony Chauvin, Nathalie ChavarotVéronique Delcey Simon Bessis, Xavier EyerCresta, MélaniePélagie Thibaut, Romain GueneauNadal, MarineSiguier, MartinBachir, MarwaValérie Pourcher, Christia PalaciosMelenotte, CléaFaycal, AntoineBerot, VincentBrin, CécileDjebara, SihamZafilaza, KarenMarot, StéphaneSayon, SophieLeducq, VincentMalet, IsabelleTeyssou, ElisaKarine Lacombe, Adélie GothlandAad, Yasmine AbiChiarabini, ThibaultFeliho, RaynaldValin, NadiaBrigant, FabienBoize, JulienThiébaud, Pierre-ClémentMoreau, MarieNathalie De Castro, Charlotte BillardLiégeon, GeoffroyDenis, BlandineMolina, Jean-MichelAndré Cabié, Lucia EtheveAbel, SylvieCabras, OrnellaGuitteaud, KarineFrançois Vincent Dubee, Sandrine Pierre-Ndiaye, DiamaPehlivan, JonathanPhelippeau, MichaelAlexandre Duvignaud, Rafael MahieuPistone, ThierryDesclaux, ArnaudNeau, DidierJean-François Faucher, Charles CazanaveFestou, BenjaminDupuy-Grasset, MagaliLoustaud-Ratti, VéroniqueNathan Peiffer- Smadja, Delphine ChainierChoquet, ChristopheDa Conceicao, OliviaThy, MichaelCollas, LioGodard, CindyBouzid, DoniaIng, VittiaroatPereira, LaurentPavlowsky, ThomasRavautAntoine Asquier-Khati, CamilleBoutoille, DavidChauveau, MarieDeschanvres, ColinAudrey Le Bot, François RaffiCailleaux, MarineBenezit, FrançoisMaillard, AnneHue, BenoitFrançois Coustilleres, Pierre TattevinCarvalho-Schneider, ClaudiaJamard, SimonPetit, LaeticiaNatacha Mrozek, Karl SteficTheis, ClémentVidal, MagaliSauvat, LéoBenjamin Lefèvre, Delphine MartineauBaronnet, GuillaumeFlorence Ader, Agnès DidierPerpoint, ThomasConrad, AnneChabert, PaulAurélie Martin, Pierre ChauvelotLoubet, PaulMazet, JulienLarcher, RomaricMathilde Devaux Jérôme Frey, Didier LaureillardWoerlen, AmosRemillon, AlineAbsensur-Vuillaume, LaureAlbert Trinh-Duc, Pauline BouquetPhilippe Petua, Patrick RispalAurore Perrot, Julien CarilloDelavigne, KarenCougoul, PierreDion, JérémieMathieu Blot, Odile RauzySixt, ThibaultMoretto, FlorianCharles, CaroleSophie Circosta, Lionel PirothLeger, LydiaArulananthan, ArulvaniLascoux, CarineValérie, PascalineYazdan Yazdanpanah, Leia BecamPetrov-Sanchez, VentzislavaDiallo, AlphaLe Mestre, SoizicLe Meut Isabelle Goderel, GuillaumeChau, FrédéricSoltana, BrahimChane Tang, JessicaGuedj, JérémieCaille, Yvanie
Source
Med; October 2023, Vol. 4 Issue: 10 p664-667, 4p
Subject
Language
ISSN
26666340
Abstract
Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.